02 December 2025

SHORTWAVE LIFE SCIENCES PLC

("Shortwave" or the "Company")

Result of Annual General Meeting

Correction to Shares in Issue

Digital Treasury Asset Management Strategy

Total Voting Rights

Shortwave Life Sciences PLC (PSY), the UK's leading healthcare company focused on developing innovative treatments for anorexia nervosa, today announces that all resolutions put to shareholders at its Annual General Meeting (AGM) held on Friday, 28 November, were duly passed.

The Company also announces a correction to the share capital statistics in the circular contained in the Notice of Annual General Meeting, announced on 4 November 2025, which overstated the issued share capital figure by 26,000,000 shares, before the Share Consolidation. Following the passing of the Resolutions, the post Share Consolidation shares in issue will be 54,260,677 Ordinary Shares of £0.0001 and 54,260,677 Deferred Shares of £0.0099. The deferred shares will not carry any economic or voting rights.

All other details remain unchanged.

Other than the change in nominal value, the New Ordinary Shares will have the same rights as the Existing Ordinary Shares, including voting and other rights. The Company's new ISIN will be GB00BNRM4F24 and new SEDOL will be BNRM4F2. The Company's ticker remains unchanged.

The Board is pleased to confirm now that the Digital Asset Treasury Policy has been approved, it can be formerly implemented.

Total Voting Rights

In accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, Shortwave hereby announces that the Company has 54,260,677 ordinary shares of £0.0001 each ("Ordinary Shares") in issue, each share carrying the right to one vote.

No shares are currently held in Treasury.

The above figure of 54,260,677 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

The Directors of the Company accept responsibility for the contents of this announcement.

Enquiries:

Company:

Rolf Gerritsen

+44 20 383 87621

Corporate Adviser:

AlbR Capital Limited:

+ 44 (0) 20 7469 0930

About Shortwave Life Sciences Plc

Shortwave Life Sciences is a developer of breakthrough therapies addressing unmet medical needs in mental health. The Company is committed to the advancement of innovative solutions through drug development, with a mission to pioneer breakthrough therapies that transform the landscape of mental health care. With a team of dedicated experts and a commitment to innovation, Shortwave Life Sciences is uniquely positioned to introduce and develop solutions for the complex challenges of mental health disorders worldwide.